Study guide

9.1 Manufacturers (Rx & OTC) & Virtual Manufacturers

PTCB Supply Chain and Inventory Management Certificate Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

Exam Facts & Logistics Eligibility & the CPhT-Adv Pathway How to Use This Guide & Study Plan

2 Chapter 2: FDA, DEA, and State Regulatory Framework

2.1 FDA Role, Jurisdiction & Drug Approval 2.2 FDA Registration & Trading-Partner Reporting 2.3 DEA Schedules & Registration 2.4 State Boards of Pharmacy & Entity Licensure

3 Chapter 3: DSCSA — Track, Trace & Transaction Data

3.1 DSCSA Scope, Products & Exceptions 3.2 Serialization, the Product Identifier & EDDS 3.3 T3 Transaction Data — TI, TH & TS 3.4 Suspect & Illegitimate Product Handling

4 Chapter 4: 340B, Hazardous Drugs, Recalls & Recordkeeping

4.1 340B Drug Pricing Program & HRSA 4.2 USP <800> & NIOSH Hazardous Drug Handling 4.3 FDA Recall Classifications & Management 4.4 Recordkeeping, Retention & Documentation

5 Chapter 5: Inventory Methods & Stock Rotation

5.1 Inventory Systems Overview 5.2 Stock Rotation, FEFO & Expiration Management 5.3 ABC Analysis, Min-Max, Par & Reorder Points 5.4 JIT, Kanban, Two-Bin & Seasonal/Emergency Forecasting

6 Chapter 6: Inventory KPIs & Math

6.1 Inventory Turnover & Days on Hand 6.2 Fill Rate, Carrying Cost & Stockout Cost 6.3 Par-Level & Reorder Calculations

7 Chapter 7: Documentation, CS Records & Automation

7.1 Documentation & File Maintenance 7.2 Controlled-Substance Records & Reporting 7.3 Automation: ADCs, Carousels & Barcoding 7.4 Cold Chain & Temperature Management

8 Chapter 8: Shortages, Contracts & Returns

8.1 Drug Shortage Mitigation & Pricing Implications 8.2 Contract Types & Compliance 8.3 Returns & Reverse Distribution

9 Chapter 9: Manufacturers, Wholesalers & 3PLs

9.1 Manufacturers (Rx & OTC) & Virtual Manufacturers 9.2 Primary Wholesale Distributors 9.3 Secondary, Specialty & OTC-Only Distributors; Virtual Wholesalers 9.4 Repackagers/Relabelers & Third-Party Logistics (3PLs)

10 Chapter 10: Compounders, Specialty & Alternative Suppliers

10.1 503A Compounding Pharmacies 10.2 503B Outsourcing Facilities 10.3 Specialty Pharmacy & Limited-Distribution Drugs 10.4 Biosimilars/Biologics, Pharmacy-to-Pharmacy Transfers & Foreign Sourcing

11 Chapter 11: Pricing, GPOs, PBMs & Health Systems

11.1 Pricing Mechanics 11.2 GPOs, IDNs & Health Systems 11.3 PBMs & ADRs

9.1 Manufacturers (Rx & OTC) & Virtual Manufacturers

Key Takeaways Explain This Topic AI

A drug manufacturer is the entity that holds FDA approval for a product and produces it; Rx drugs reach market via NDA, ANDA, or BLA, while OTC drugs reach market via an FDA monograph or an NDA

All drug manufacturers must register with FDA and list each drug they make (NDC registration); FDA-registered facilities are subject to cGMP inspection

Under DSCSA, manufacturers must serialize packages with a product identifier and pass transaction information and a transaction statement to the next trading partner (transaction history ended November 27, 2023)

Manufacturers normally sell to wholesale distributors; direct-to-pharmacy or direct-to-hospital sales exist but are less common and still trigger DSCSA obligations

A virtual manufacturer owns the product and the FDA approval but contracts out physical production to a contract manufacturer and logistics to a 3PL — it is still a DSCSA trading partner and must register with FDA

Last updated: September 2026

The manufacturer sits at the very top of the pharmaceutical supply chain. It is the entity that holds the FDA approval for a drug and produces (or arranges production of) that drug. Everything downstream — wholesalers, repackagers, 3PLs, pharmacies — traces product back to a manufacturer. For the PTCB Supply Chain exam, you must know how Rx and OTC manufacturers reach market, what FDA registration they carry, and what DSCSA places on them.

How Drugs Reach Market: Rx vs OTC

Prescription (Rx) and over-the-counter (OTC) drugs take different regulatory pathways to market, and that difference shapes what the manufacturer must do.

Prescription Drugs — NDA, ANDA, and BLA

A new Rx drug reaches market through one of three FDA approval pathways:

New Drug Application (NDA) — used for a new molecular entity or a major change to an existing product. The NDA is the most demanding pathway, requiring full clinical evidence of safety and efficacy. The manufacturer that holds an approved NDA is the reference listed drug (RLD) holder.

Abbreviated New Drug Application (ANDA) — used for a generic drug. The ANDA applicant must demonstrate bioequivalence to the RLD but does not repeat the clinical trials. An ANDA holder is a manufacturer of a generic drug.

Biologics License Application (BLA) — used for biological products (e.g., monoclonal antibodies, vaccines, biosimilars). A biosimilar is approved under a BLA, not an NDA.

OTC Drugs — Monograph or NDA

An OTC drug generally reaches market in one of two ways:

OTC Monograph — FDA publishes a final monograph specifying the active ingredient, dose, indications, and labeling. A manufacturer that follows the monograph can market the OTC drug without a separate NDA . The monograph essentially pre-approves the product class.

NDA — some OTC drugs (e.g., those first approved as Rx and then switched to OTC) are marketed under an NDA rather than under a monograph.

The exam often tests the monograph pathway as the OTC-specific route distinct from the Rx NDA/ANDA/BLA routes.

FDA Registration and Drug Listing

Every facility that manufactures a drug for the U.S. market must register with FDA and submit a National Drug Code (NDC) listing for each drug. Registration is the mechanism that places the facility under FDA inspection for current Good Manufacturing Practice (cGMP) . cGMP covers everything from facility design and sanitation to batch records, stability testing, and quality release — a batch that fails cGMP release cannot legally enter commerce.

Key points the exam rewards:

FDA registration is required of manufacturers — it is not optional.

NDC listing assigns the 10- or 11-digit NDC that downstream trading partners use to identify the product.

cGMP compliance is enforced through FDA inspection; a Form 483 may be issued for observed violations.

DSCSA Obligations on Manufacturers

Under the Drug Supply Chain Security Act (DSCSA) , a manufacturer of a covered prescription product is an authorized trading partner and carries specific obligations:

Serialization — the manufacturer must affix a product identifier (National Drug Code, serial number, lot number, and expiration date) in both human-readable and machine-readable (2D Data Matrix) form to each package. Serialization is the foundation of package-level traceability.

Transaction data — when the manufacturer sells or transfers ownership of a covered product to the next trading partner, it must pass Transaction Information (TI) and Transaction Statement (TS) . TI contains the product identifier, lot, expiration date, transaction date, and quantity; TS is the attestation by the seller. A third document, Transaction History (TH) — the cumulative chain of ownership back to the manufacturer — was historically part of this set but has not been required since section 582(k)(1)'s November 27, 2023 sunset.

Suspect and illegitimate product — the manufacturer must investigate and notify FDA and immediate trading partners if it determines product is suspect or illegitimate, and must quarantine and not distribute illegitimate product.

Verification — the manufacturer must respond to verification requests (e.g., a downstream dispenser asking "is this package legitimate?") within a specified timeframe.

Note that OTC monograph drugs are generally outside DSCSA . The serialization and T3 obligations attach to covered prescription products , which is why a technician must not assume every drug in the building carries T3 paper.

Manufacturer Sales Channels

The normal flow is manufacturer → wholesale distributor → pharmacy/hospital . Manufacturers sell the large majority of volume to wholesalers, who aggregate and distribute. Two narrower channels also exist:

Direct-to-pharmacy / direct-to-hospital — some manufacturers (especially of specialty, limited-distribution, or cold-chain biologics) ship directly to a pharmacy or health system, bypassing the wholesaler. This is common for limited-distribution drugs (LDDs) and some specialty products.

Authorized distribution network — a manufacturer may designate certain wholesalers as authorized distributors of its products. Product sold through the authorized network is presumptively genuine; product appearing outside that network raises a diversion flag.

Regardless of channel, DSCSA obligations follow the product : a manufacturer that sells direct to a hospital must still pass T3 data to that hospital.

Virtual Manufacturers

A virtual manufacturer is an entity that owns the product and the FDA approval (the NDA, ANDA, or BLA is held in its name) but outsources the physical work : a contract manufacturer makes the drug, and a Third-Party Logistics provider (3PL) warehouses and ships it. The virtual manufacturer does not operate its own production line or its own warehouse.

Why this matters for the exam:

A virtual manufacturer is still a manufacturer for regulatory purposes — it must register with FDA , it is an authorized trading partner under DSCSA, and it must serialize and pass T3 .

The fact that physical handling is contracted out does not move the virtual manufacturer into the "wholesaler" or "3PL" box. Ownership of the approval — not ownership of the building — defines the role.

A common exam trap is to treat a virtual manufacturer as something less than a manufacturer because it has no factory. The correct view is the opposite: it carries the same manufacturer obligations, layered on top of contract oversight of its contract manufacturer and 3PL.

Summary Table — Manufacturer Types

  • Type Approval Path FDA Registered DSCSA Serialization/T3? Notes
  • Brand Rx manufacturer NDA Yes Yes (covered Rx) Holds the RLD
  • Generic manufacturer ANDA Yes Yes (covered Rx) Must show bioequivalence
  • Biologic/biosimilar manufacturer BLA Yes Yes (covered Rx) Vaccines, mAbs, biosimilars
  • OTC monograph manufacturer OTC monograph Yes Generally no (outside DSCSA) Follows the monograph
  • Virtual manufacturer Holds NDA/ANDA/BLA Yes Yes (covered Rx) Outsources production to a contract manufacturer

The unifying rule: registration and DSCSA obligations attach to the entity that holds the approval and puts the product into commerce , whether or not it runs the factory. The pathway (NDA/ANDA/BLA/monograph) determines the approval burden; DSCSA determines the downstream traceability burden.